InterMune Given Average Rating of “Buy” by Analysts (NASDAQ:ITMN)
InterMune (NASDAQ:ITMN) has been given a consensus rating of “Buy” by the fifteen ratings firms that are presently covering the stock, AnalystRatings.NET reports. Two equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $44.31.
Shares of InterMune (NASDAQ:ITMN) traded up 1.55% on Thursday, hitting $44.925. 1,157,864 shares of the company’s stock traded hands. InterMune has a 52-week low of $10.95 and a 52-week high of $47.72. The stock’s 50-day moving average is $44.1 and its 200-day moving average is $33.46. The company’s market cap is $4.442 billion.
InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the previous year, the company posted ($0.77) earnings per share. The company’s revenue for the quarter was up 141.2% on a year-over-year basis. Analysts expect that InterMune will post $-2.32 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Robert W. Baird raised their price target on shares of InterMune from $44.00 to $50.00 in a research note on Thursday. Finally, analysts at Jefferies Group raised their price target on shares of InterMune from $22.00 to $25.00 in a research note on Thursday.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.